ChoironeX GalKO Porcine Thymokidney

Phase 1

ChoironeX GalKO Porcine Thymokidney is one of 2 therapeutic programs targeting End-Stage Renal Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

End-Stage Renal DiseaseNot yet recruiting

End-Stage Renal DiseasePhase 1

Not yet recruiting

Competition

Competitive Landscape

3 competitors in End-Stage Renal Disease

#DrugCompanyPhaseTrials

Avastin

BBio-Thera Solutions

Phase 1

1 2

ChoironeX GalKO Porcine Thymokidney

XXeno Holdings (US), LLC dba ChoironeX

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

End-Stage Renal Disease

NCT07696962

Clinical

Trials by Indication[1]

End-Stage Renal Disease1 trial

Phase 1 Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease

Not yet recruiting·XXeno Holdings (US), LLC dba ChoironeX·Phase 1·NCT07696962·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ChoironeX GalKO Porcine Thymokidney. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for ChoironeX GalKO Porcine Thymokidney. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Xeno Holdings (US), LLC dba ChoironeX company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: XXeno Holdings (US), LLC dba ChoironeX

ChoironeX GalKO Porcine Thymokidney

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

End-Stage Renal Disease1 trial

References

Drug Info

Quick Facts

Related News